Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

Withdrawn before enrolling

Conditions studied: McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus

In brief

The investigators' objective is to understand the pathogenesis of diabetes mellitus in Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by: 1) establishing the contributions of insulin resistance versus impaired insulin secretion, 2) investigating presence of excess glucagon signaling by measuring gluconeogenesis and glycogenolysis, and 3) investigating a potential interaction between diabetes and intraductal papillary mucinous neoplasms (IPMNs).

Key facts

Study ID

NCT03520153

Run by

Yale University

People needed

0

Starts

2018-08-07

Expected to finish

2021-08-01

Last updated by the study team

2019-09-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) group:
• Must be diagnosed based on clinical grounds and/or mutation testing on bone and/or affected tissue
• Control group:
• Must be at least 18 years old

You may not qualify if…

• Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) group:
• Unwilling to fully cooperate with the evaluation
• Unable to provide informed consent
• Control group:
• History of diabetes, insulin resistance, pancreatic disease, pancreatic cysts or amylase/lipase abnormality
• Use of any type of oral diabetes medications and/or insulin
• Unable to provide informed consent

Where it is running

• Yale New Haven Hospital — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.